Trial Profile
Study of a comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis (RRMS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2018
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab (Primary) ; Dimethyl fumarate; Glatiramer acetate; Interferon beta; Teriflunomide
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 11 May 2018 New trial record
- 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology